Trailing-twelve-month (TTM) revenue is $15.41 Billion with a year-over-year growth of +1.76%. Revenue represents the total income generated from the company's primary business operations.
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-28 | $3,764,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-03 |
| Q4 FY2025Period ended 2025-12-28 | $3,780,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-02-20 |
| Q1 FY2026Period ended 2026-03-29 | $3,909,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-07 |
| Q2 FY2026Period ended 2026-06-28 | $3,955,000,000 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-06 |
| TTM revenue | $15,408,000,000 |
Current P/S: $33,926,553,164 market capitalization ÷ $15,408,000,000 TTM revenue = 2.20x.
Market capitalization source: FMP quote. Quote observed 2026-09-23T20:00:02.000Z. Latest revenue period ended 2026-06-28.
Current market capitalization comes from the quote provider. EPS weighted-average shares are a separate measure.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
Reported quarterly revenue; no daily interpolation. Q2 FY2026 (2026-06-28): $3.96B.
Revenue growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters Quote observation: 2026-09-24T00:16:05.277Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
2025-12-28 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|---|
| Essential Health | $4.6B | $4.7B | $4.6B |
| Self Care | $6.5B | $6.5B | $6.4B |
| Skin Health and Beauty | $4.4B | $4.2B | $4.1B |
FMP selected disclosures by reporting period. Rows match exact source labels; they may overlap. N/A means no matching disclosure, not zero. Filing links identify reviewed presentation labels for that period.
| FMP source label (unverified unless linked) | FY20232023-12-31 · USD | FY20242024-12-29 · USD | FY20252025-12-28 · USD |
|---|---|---|---|
| Asia Pacific | $3.1B | $3.0B | $2.8B |
| EMEA | $3.4B | $3.6B | $3.7B |
| Latin America | $1.3B | $1.3B | $1.4B |
| North America | $7.6B | $7.6B | $7.3B |
$15.41B
$15.41 Billion
+1.76%
vs. $15.14B a year ago (TTM)
+0.89%
5 Year compound annual growth rate
1 Year
+1.76%
3 Year
+0.43%
5 Year
+0.89%
10 Year
N/A
15 Year
N/A
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $15.12B | ($331.00M) | (2.14%) |
| 2024 | $15.46B | +$11.00M | +0.07% |
| 2023 | $15.44B | +$494.00M | +3.30% |
| 2022 | $14.95B | ($104.00M) | (0.69%) |
| 2021 | $15.05B | +$587.00M | +4.06% |
| 2020 |
TTM Growth
+1.76%
3-Year CAGR
+0.43%
5-Year CAGR
+0.89%
Current FMP quote-based enterprise value / four-quarter revenue Quote observation: 2026-09-24T00:16:05.277Z. Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation. Historical series through 2026-09-11.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
| $14.47B |
| +$143.00M |
| +1.00% |
